HµREL® : HUMAN-RELEVANT cell based and microfluidic systems.
HµREL® Corporation develops advanced liver tissue constructs and microfluidic cell-based assay platforms for pre-clinical predictive toxicology, drug metabolism and pharmacokinetics. HµREL®’s stable, high-functioning metabolic competency and long endurance, enable novel in-vitro experiments including long-term multiple dosing toxicity, metabolic clearance, long-term CYP inhibition or metabolite generation studies. HµRELflow recirculating microfluidics allow for multi-tissue interactions.
Copyright 2014, a2z, Inc. All rights reserved.